沙库巴曲缬沙坦对持续性房颤患者心脏结构和功能及心肌纤维化指标影响的研究
Effect of Sacubitril Valsartan Sodium Hydrate on Patients with Persistent Atrial Fibrillation Study on the Influence of Cardiac Structure and Function and Myocardial Fibrosis Index
DOI: 10.12677/ACM.2021.1112908, PDF,    科研立项经费支持
作者: 朱博文：青海大学研究生院，青海 西宁；苏晓灵*：青海省人民医院心血管内科，青海 西宁
关键词: 持续性心房颤动；沙库巴曲缬沙坦；心脏结构及功能；心肌纤维化；Persistent Atrial Fibrillation； Sacubitril Valsartan Sodium Hydrate； Cardiac Structure and Function； Myocardial Fibrosis
摘要: 心房颤动作为一种最常见的心律失常之一，其中持续性心房颤动对心脏结构及心肌纤维化方面的作用最为显著。而沙库巴曲缬沙坦的问世对于心房颤动所引起的心脏结构及心肌纤维化的改变有一定的影响，在治疗心房颤动方面提供了新的治疗方案及进展，因此本文将对持续性心房颤动的发病机制、沙库巴曲缬沙坦药理机制及沙库巴曲缬沙坦钠在持续性心房颤动患者的心脏结构及心肌纤维化指标的影响进行综述。
Abstract: Atrial fibrillation is one of the most common arrhythmias, in which persistent atrial fibrillation has the most significant effect on cardiac structure and myocardial fibrosis. The advent of sacubitril valsartan sodium hydrate has a certain impact on the changes of cardiac structure and myocardial fibrosis caused by atrial fibrillation, and provides a new treatment scheme and progress in the treatment of atrial fibrillation. Therefore, this paper will study the pathogenesis of persistent atrial fibrillation and reviews the pharmacological mechanism of sacubitril valsartan sodium hydrateand the effects of sacubitril valsartan sodium hydrate on cardiac structure and myocardial fibrosis in patients with persistent atrial fibrillation.
文章引用：朱博文, 苏晓灵. 沙库巴曲缬沙坦对持续性房颤患者心脏结构和功能及心肌纤维化指标影响的研究[J]. 临床医学进展, 2021, 11(12): 6123-6128. https://doi.org/10.12677/ACM.2021.1112908

参考文献

[1] Hindricks, G., Potpara, T., Dagres, N., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42, 373-498. [Google Scholar] [CrossRef] [PubMed]
[2] John-Camm, A., Simantirakis, E., Goette, A., et al. (2017) Atrial High-Rate Episodes and Stroke Prevention. EP Europace, 19, 169-179. [Google Scholar] [CrossRef] [PubMed]
[3] 陈颖. 利尿合剂对慢性心力衰竭患者炎症因子的干预作用研究[J]. 中国疗养医学, 2017, 26(12): 1319-1320.
[4] Andrade, J., Khairy, P., Dobrev, D., et al. (2014) The Clinical Profile and Pathophysiology of Atrial Fibrillation: Relationships among Clinical Features, Epidemiology, and Mechanisms. Circulation Research, 114, 1453-1468. [Google Scholar] [CrossRef] 
[5] Miragoli, M. and Glukhov, A.V. (2015) Atrial Fibrillation and Fibrosis: Beyond the Cardiomyocyte Centric View. BioMed Research International, 2015, Article ID: 798768. [Google Scholar] [CrossRef] [PubMed]
[6] Lau, D.H., Linz, D. and Sanders, P. (2019) New Findings in Atrial Fibrillation Mechanisms. Cardiac Electrophysiology Clinics, 11, 563-571. [Google Scholar] [CrossRef] [PubMed]
[7] 郑金轩, 赵继义. 心外膜脂肪组织对心房颤动影响的研究进展[J]. 医学综述, 2019, 25(14): 2811-2815.
[8] Zou, R., Yang, M., Shi, W., et al. (2018) Analysis of Genes Involved in Persistent Atrial Fibrillation: Comparisons of “Trigger” and “Substrate” Differences. Cellular Physiology and Biochemistry, 47, 1299-1309. [Google Scholar] [CrossRef] [PubMed]
[9] 侯婷婷, 刘广忠, 陶源, 等. 心房颤动与心房重构研究的最新进展[J]. 现代生物医学进展, 2017, 17(35): 6972-6975.
[10] Qin, M., Zeng, C. and Liu, X. (2019) The Cardiac Autonomic Nervous System: A Target for Modulation of Atrial Fibrillation. Clinical Cardiology, 42, 644-652. [Google Scholar] [CrossRef] [PubMed]
[11] Carnagarin, R., Kiuchi, M.G., Ho, J.K., et al. (2018) Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. Frontiers in Neuroscience, 2018, Article ID: 121058. [Google Scholar] [CrossRef] [PubMed]
[12] Grunnet, M., Bentzen, B.-H., Sorensen, U.-S., et al. (2012) Cardiac ion Channels and Mechanisms for Protection against Atrial Fibrillation. Reviews of Physiology, Biochemistry and Pharmacology, 1621-1658.
[13] Korantzopoulos, P., Letsas, K.P., Tse, G., et al. (2018) Inflammation and Atrial Fibrillation: A Comprehensive Review. Journal of Arrhythmia, 34, 394-401. [Google Scholar] [CrossRef] [PubMed]
[14] Scott, L., Li, N. and Dobrev, D. (2019) Role of Inflammatory Signaling in Atrial Fibrillation. International Journal of Cardiology, 287, 195-200. [Google Scholar] [CrossRef] [PubMed]
[15] Harada, M., Van Wagoner, D.R. and Nattel, S. (2015) Role of Inflammation in Atrial Fibrillation Pathophysiology and Management. Circulation Journal, 79, 495-502. [Google Scholar] [CrossRef] 
[16] Ren, J.F., Marchlinski, F.E. and Callans, D.J. (2004) Left Atrial Thrombus Associated with Ablation for Atrial Fibrillation: Identification with Intracardiac Echocardiography. Journal of the American College of Cardiology, 43, 1861-1867. [Google Scholar] [CrossRef] [PubMed]
[17] Docherty, K.-F., Vaduganathan, M., Solomon, S.-D., et al. (2020) Sacubitril/Valsartan: Neprilysin Inhibition 5 Years after PARADIGM-HF. JACC Heart Fail, 8, 800-810. [Google Scholar] [CrossRef] [PubMed]
[18] Hanefeld-Fox, L., Lissette, J., Rebecca, H., et al. (2018) Sacubitril/Valsartan-Associated Small Bowel Ileus. American Journal of Therapeutics, 25, E705-E706. [Google Scholar] [CrossRef] 
[19] Weir, R.-A.-P. (2019) Sacubitril/Valsartan and Mexiletine: A Proarrhythmic Combination? Cardiology, 142, 4-6. [Google Scholar] [CrossRef] [PubMed]
[20] Ilana, F., Lam, C., Talreja, O., et al. (2020) Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia. Journal of Pharmacy Practice, 33, 696-699. [Google Scholar] [CrossRef] [PubMed]
[21] Vodovar, N., Helene, N., Jean-Marie, L., et al. (2017) Sacubitril/Valsartan in PARADIGM-HF. The Lancet. Diabetes & Endocrinology, 5, 495-496. [Google Scholar] [CrossRef] 
[22] 陆益, 胡伟, 尹桂芝, 等. 诺欣妥对难治性心力衰竭患者心室重构及预后的影响研究[J]. 现代生物医学进展, 2019, 19(13): 2498-2501.
[23] 秦丽英, 李平宝, 范尧, 等. 诺欣妥对持续性房颤合并慢性心衰患者心功能和生活质量的影响[J]. 北方药学, 2020, 17(1): 133-134.
[24] Li, L.-Y., Lou, Q., Liu, G.-Z., et al. (2020) Sacubitril/Valsartan Attenuates Atrial Electrical and Structural Remodelling in a Rabbit Model of Atrial Fibrillation. European Journal of Pharmacology, 881, Article ID: 173120. [Google Scholar] [CrossRef] [PubMed]
[25] De Vecchis, R., Paccone, A. and Di Maio, M. (2020) Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. Cardiology Research, 11, 213-218. [Google Scholar] [CrossRef] [PubMed]
[26] De Vecchis, R., Paccone, A. and Di Maio, M. (2020) Favorable Effects of Sacubitril/Valsartan on the Peak Atrial Longitudinal Strain in Patients with Chronic Heart Failure and a History of One or More Episodes of Atrial Fibrillation: A Retrospective Cohort Study. Journal of Clinical Medicine Research, 12, 100-107. [Google Scholar] [CrossRef] [PubMed]
[27] Thomas, H.E. and Olgin, J.E. (2007) Atrial Fibrosis and the Mechanisms of Atrial Fibrillation. Heart Rhythm, 4. [Google Scholar] [CrossRef] [PubMed]
[28] 李发鹏, 甘天翊, 姜涛, 等. 基质金属蛋白酶-9及组织抑制因子-1在老年犬持续性心房颤动心房组织中表达[J]. 中华实用诊断与治疗杂志, 2012, 26(3): 223-226.
[29] 王文俊, 纪亚梅. 金属蛋白酶组织抑制因子-1对心室重构影响的研究进展[J]. 临床合理用药杂志, 2012, 5(18): 167.
[30] Sun, H.P., Kristine, C.O., Chen, G., et al. (2016) Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation, 133, 2038-2049. [Google Scholar] [CrossRef] 
[31] 董闻平, 蒋金金. 血清MMP-9 TIMP-1浓度及左房内径与心房颤动类型的关系[J]. 中国药物与临床, 2012, 12(8): 1029-1030.
[32] Suo, Y., Yuan, M., Li, H., et al. (2019) Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients with Atrial Fibrillation and in Pressure Overload-Induced Mice. Frontiers in Pharmacology, 2019, Article ID: 101285. [Google Scholar] [CrossRef] [PubMed]
[33] Zile, M.R., O’Meara, E., Claggett, B., et al. (2019) Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients with HFrEF. Journal of the American College of Cardiology, 73, 795-806. [Google Scholar] [CrossRef] [PubMed]

为你推荐